Arcus Biosciences Elects New Directors, Adjusts Executive Pay
Ticker: RCUS · Form: 8-K · Filed: Jan 21, 2025 · CIK: 1724521
Sentiment: neutral
Topics: board-changes, executive-compensation, personnel
TL;DR
Arcus adds 2 directors, updates exec pay. Board shakeup incoming?
AI Summary
Arcus Biosciences, Inc. announced on January 16, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company elected two new directors, Dr. David J. Earp and Ms. Jennifer L. Jones, to its Board of Directors. Additionally, the company entered into new employment agreements with certain executive officers, including Dr. Terry P. Young (Chief Medical Officer) and Ms. Jennifer L. Jones (Chief Financial Officer), detailing their compensation and benefits.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can introduce uncertainty regarding future strategic direction and management stability.
Key Players & Entities
- Arcus Biosciences, Inc. (company) — Registrant
- Dr. David J. Earp (person) — Newly elected Director
- Ms. Jennifer L. Jones (person) — Newly elected Director and Chief Financial Officer
- Dr. Terry P. Young (person) — Chief Medical Officer
- January 16, 2025 (date) — Date of earliest event reported
FAQ
Who are the newly elected directors to Arcus Biosciences' Board?
Dr. David J. Earp and Ms. Jennifer L. Jones were elected to the Board of Directors.
What is the date of the earliest event reported in this 8-K filing?
The earliest event reported is dated January 16, 2025.
What is Ms. Jennifer L. Jones' role in addition to being a new director?
Ms. Jennifer L. Jones is also the Chief Financial Officer of Arcus Biosciences.
What specific items are being reported under the 8-K filing?
The filing reports on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What is the principal executive office address for Arcus Biosciences?
The principal executive offices are located at 3928 Point Eden Way, Hayward, California 94545.
Filing Stats: 530 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-01-21 16:11:18
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share RCUS The New York Stock Excha
Filing Documents
- rcus-20250116.htm (8-K) — 25KB
- 0001724521-25-000005.txt ( ) — 144KB
- rcus-20250116.xsd (EX-101.SCH) — 2KB
- rcus-20250116_lab.xml (EX-101.LAB) — 21KB
- rcus-20250116_pre.xml (EX-101.PRE) — 12KB
- rcus-20250116_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCUS BIOSCIENCES, INC. Date: January 21, 2025 By: /s/ Terry Rosen, Ph. D. Terry Rosen, Ph.D. Chief Executive Officer (Principal Executive Officer)